Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis.
BACKGROUND
Recently, more and more evidences have revealed the association between CD44V6 and osteosarcoma (OS), but whether it can be used as a clinical biomarker is still unknown. The purpose of this study is to assess the diagnostic value of CD44V6 in OS by conducting a meta-analysis.


METHODS
All relevant electronic literatures were collected from seven international databases together with three Chinese databases up to April 23, 2016. Eligible studies were selected through multiple search strategies and the quality was assessed by QUADAS. Data was extracted from studies according to the key statistics index. All analyses were performed using STATA 12 and Meta-DiSc 1.4 statistical software.


RESULTS
According to the exclusion and inclusion criteria, 8 literatures were retrieved, accounting for 463 cases and 188 controls. For discriminating OS from benign bone tumor or healthy controls, the area under the receiver operating characteristic curve (AUC) was 0.91 (95 % CI 0.88-0.93). Overall, the results showed pooled sensitivity of 0.743 (95 % CI 0.606-0.844) and specificity of 0.897 (95 % CI 0.818-0.945), respectively. Substantial heterogeneity was detected in this study (I2= 90 %). The publication bias was assessed by using Deeks' asymmetry test (p = 0.795). No evidence of heterogeneity from threshold effects was detected by the Spearman correlation coefficient (-0.506, p = 0.201). Meta-regression was performed to mining the source of heterogeneity, and subgroup analysis showed that neither the cut-off values nor the control groups were the source of heterogeneity.


CONCLUSIONS
The present results suggest that promoted CD44V6 expression levels are associated with OS and CD44V6 may be used as a diagnostic marker for OS.
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Yunyuan
Y
Zhang
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Limin
L
Lun
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Baozhi
B
Zhu
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Qing
Q
Wang
Department of Orthopedic Surgery, Qingdao Municipal Hospital, Qingdao, 266011, People's Republic of China.
Chunming
C
Ding
Department of Trauma Surgery, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Yanlin
Y
Hu
Department of Infection Control, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Weili
W
Huang
College of Laboratory Medicine, Key Laboratory of Laboratory Medical Diagnostics designated by Chinese Ministry of Education, Chongqing Medical University, Chongqing, 400016, China.
Lan
L
Zhou
Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China. cxkakicoco2014@163.com.
Xian
X
Chen
Department of Clinical Biochemistry, School of Clinical Laboratory Science, Guizhou Medical University, Guiyang, 550004, Guizhou Province, China. huanghai828@gmc.edu.cn.|Department of Clinical Biochemistry, Affiliated Hospital of Guizhou Medical University, Guiyang, 550004, Guizhou Province, China. huanghai828@gmc.edu.cn.
Hai
H
Huang
D014408:Biomarkers, Tumor / Q000378:metabolism; D001859:Bone Neoplasms / Q000175:diagnosis*; D055088:Early Detection of Cancer; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D012516:Osteosarcoma / Q000175:diagnosis*; D012372:ROC Curve; D012680:Sensitivity and Specificity
D014408:Biomarkers, Tumor; C112697:CD44v6 antigen; D018960:Hyaluronan Receptors
CD44V6; Diagnosis; Meta-analysis; Osteosarcoma